Standout Papers

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis ... 2015 2026 2018 2022 640
  1. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Iain B. McInnes, Philip J. Mease et al. The Lancet

Citation Impact

4 from Science/Nature 56 standout
Sub-graph 1 of 20

Citing Papers

Recent Advances in 3D Printing of Smart Scaffolds for Bone Tissue Engineering and Regeneration
2024 Standout
From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
2 intermediate papers

Works of Manmath Patekar being referenced

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
2015 Standout

Author Peers

Author Immunology Dermatology Hematology Rheumatology Last Decade Papers Cites
Manmath Patekar 900 347 387 501 20 1.1k
Paulina Torres‐Rodríguez 21 1 13 304
Nilton Bila 7 43
Alan Bender 48 12 1 20 2.5k
Marieke van Deursen 9 324
Errez Shapir 7 307

All Works

Loading papers...

Rankless by CCL
2026